Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/111874
Authors: 
Bhaduri, Saradindu
Brenner, Thomas
Year of Publication: 
2011
Series/Report no.: 
Working Papers on Innovation and Space 05.11
Abstract: 
The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in contrast, have diverse disease profiles and weaker forms of regulation. A limited set of studies, undertaken in recent years, on the diffusion of new drugs in developing countries indeed conjectures importance of such factors in shaping drug launch dynamics. We investigate the delay of new drug launch in India for drugs launched in the German market during 1990-2004, when, due to weak IPR, not only the innovators but also the domestic firms could launch new drug molecules in the country, making drug launch dynamics interesting to explore. The paper finds that global commercial success of a new drug, market share, first mover advantage, and the threat of imposition of strong IPR system shortens delay. Innovativeness of a new drug, surprisingly, does not have much significant impact on delay.
Subjects: 
Drug launch delay
Germany
India
survival analysis
JEL: 
O10
O30
O33
O34
O53
L20
C14
L65
Document Type: 
Working Paper

Files in This Item:
File
Size
139.71 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.